Company news

Tarsus Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

February 21, 2024

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

February 19, 2024

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

January 30, 2024

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

December 10, 2023

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

November 8, 2023

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 31, 2023

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

September 5, 2023

Tarsus to Present at Upcoming Investor Conferences

August 29, 2023

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

August 23, 2023

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

August 9, 2023

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

July 31, 2023

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

July 30, 2023

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

July 24, 2023

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

June 11, 2023

Tarsus to Present at the Jefferies Global Healthcare Conference

June 4, 2023

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

May 8, 2023

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

May 7, 2023

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

May 2, 2023

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

April 23, 2023

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

March 12, 2023

Tarsus Added to NASDAQ Biotechnology Index

December 15, 2022

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

December 14, 2022

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

November 8, 2022

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

October 24, 2022

Tarsus Announces Transition Plans for Board of Directors

October 10, 2022

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

October 5, 2022

Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

September 28, 2022

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

September 26, 2022

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

September 6, 2022

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

August 10, 2022

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

August 4, 2022

Tarsus to Present at the Jefferies 2022 Healthcare Conference

May 26, 2022

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

May 9, 2022

Tarsus to Present at Bank of America 2022 Healthcare Conference

May 5, 2022

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

May 4, 2022

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

May 2, 2022

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

May 1, 2022

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

May 1, 2022

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

April 28, 2022

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

April 25, 2022

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

March 13, 2022

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

February 2, 2022

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

February 1, 2022

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

February 1, 2022

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

January 3, 2022

Tarsus to Participate at Upcoming Virtual Investor Conferences

November 22, 2021

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

November 9, 2021

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

November 8, 2021

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

November 3, 2021

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

November 1, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.